Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04613661
Other study ID # 2020-GOKAE-0450
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 20, 2020
Est. completion date December 17, 2021

Study information

Verified date February 2022
Source Izmir Katip Celebi University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The reliability of the Australian Spasticity Assessment Scale (ASAS) has been reported to be not high enough in adult patients with acquired brain damage. The low number of patients and the heterogeneous study population have been reported as important limitations in the reliability study of this measure. Therefore, the reliability of the ASAS needs to be confirmed in stroke patients with spasticity. This study aims to investigate the inter-rater reliability of the ASAS in a study population consisting of a larger and more homogeneous patient population (those with post-stroke spasticity).


Description:

Spasticity is a motor disorder characterized by a velocity-dependent increase in tonic stretch reflex due to upper motor neuron lesion. The prevalence of post-stroke spasticity is between 17-40%. In the assessment of spasticity, although biomechanical and neurophysiological methods provide quantitative data, semi-quantitative methods are mostly used clinically. The most frequently used spasticity measures are the Modified Ashworth Scale and the Modified Tardieu Scale. However, these methods have significant disadvantages. Therefore, the search for more reliable clinical measures continues. One of the newly developed clinical scales is called the Australian Spasticity Assessment Scale (ASAS). Although ASAS has been reported to have a high level of reliability in children with cerebral palsy, the same has not been detected in adult patients with acquired brain damage. The low number of patients and the heterogeneous study population have been reported as two of the important limitations in the reliability study of this measure. In this study, researchers aim to investigate the inter-rater reliability of the ASAS in a study population consisting of a larger and more homogeneous patient population (those with post-stroke spasticity).


Recruitment information / eligibility

Status Completed
Enrollment 85
Est. completion date December 17, 2021
Est. primary completion date December 17, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Chronic stroke (> 6 months) - Fist stroke - Increased tone according to the Modified Ashworth Scale in at least one of the elbow, wrist, and ankle - Stability of spasticity for the last 3 months Exclusion Criteria: - Increased tone due to causes other than stroke (traumatic brain injury, spinal cord injury, multiple sclerosis, motor neuron disease, etc.) - Acute or subacute stroke (=6 months) - Recurrent stroke attacks - Presence of contracture and/or moderate to severe pain in the joints to be assessed (elbow, wrist, and ankle) - Botulinum toxin injection in the last three months - History of neurolysis for spasticity (alcohol or phenol) - History of surgery for spasticity - Initiation of a new drug for spasticity, or a change in drug dose

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Australian Spasticity Assessment Scale
Australian Spasticity Assessment Scale is a clinical measure to assess the severity of spasticity

Locations

Country Name City State
Turkey Ilker Sengül Izmir

Sponsors (1)

Lead Sponsor Collaborator
Izmir Katip Celebi University

Country where clinical trial is conducted

Turkey, 

References & Publications (7)

Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987 Feb;67(2):206-7. — View Citation

Calame A, Singer B. Inter- and Intra-Rater Reliability of the Australian Spasticity Assessment Scale in Adults with Acquired Brain Injury. Open Journal of Therapy and Rehabilitation. 2015;3:77-86.

Lance JW. The control of muscle tone, reflexes, and movement: Robert Wartenberg Lecture. Neurology. 1980 Dec;30(12):1303-13. — View Citation

Love S, Gibson N, Smith N, Bear N, Blair E; Australian Cerebral Palsy Register Group. Interobserver reliability of the Australian Spasticity Assessment Scale (ASAS). Dev Med Child Neurol. 2016 Feb;58 Suppl 2:18-24. doi: 10.1111/dmcn.13000. Epub 2016 Jan 14. — View Citation

Lundström E, Terént A, Borg J. Prevalence of disabling spasticity 1 year after first-ever stroke. Eur J Neurol. 2008 Jun;15(6):533-9. doi: 10.1111/j.1468-1331.2008.02114.x. Epub 2008 Mar 18. — View Citation

Pierson SH. Outcome measures in spasticity management. Muscle Nerve Suppl. 1997;6:S36-60. Review. — View Citation

Wissel J, Manack A, Brainin M. Toward an epidemiology of poststroke spasticity. Neurology. 2013 Jan 15;80(3 Suppl 2):S13-9. doi: 10.1212/WNL.0b013e3182762448. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Australian Spasticity Assessment Scale (ASAS) The ASAS is an ordinal scale with five levels (0, 1, 2, 3, 4). The severity of spasticity increases as the level-ups.The contracture is assessed separately. Level 0 means no catch on rapid passive stretch (no spasticity), and level 4 means that the body part is fixed on the rapid passive stretch but moves on the slow passive stretch. In level 1, a catch followed by a release occurs on the rapid passive stretch. In level 2, the catch is in the second half of the range, and there is a resistance in the remaining range of motion. In level 3, the catch is in the first half of the range, and there is a resistance in the remaining range of motion. Through study completion, an average of 2 year
See also
  Status Clinical Trial Phase
Terminated NCT04113525 - Transcutaneous Spinal and Peripheral Stimulation and Wrist Robotic Therapy for Patients With Spastic Stroke N/A
Completed NCT03321097 - Condensed and Distributed Robotic Therapy in Spastic Stroke Post Botulinum Toxin Injection N/A
Not yet recruiting NCT03621423 - The Use of Ultrasound for Botulinum Toxin Subscapularis Muscle Injection Guidance in Spastic Hemiplegic Shoulder Pain N/A
Completed NCT03788629 - THE EFFECTS OF SUBTALAR JOINT MOBILIZATION ON PATIENTS WITH CHRONIC STROKE N/A
Completed NCT03807557 - Robotic Modified Constraint -Induced Therapy in Patients With Spastic Hemiplegic Stroke Post Botulinum Toxin A Injection N/A
Completed NCT04939493 - Use of Rhythmic Auditory Cueing During Bilateral Training of the Upper Extremities in Stroke Patients N/A
Recruiting NCT05557305 - Changes in Motor and Cognitive Function on Unilateral Spastic Cerebral Palsy, Associated With Videogame Therapy N/A
Completed NCT05889026 - The Effect of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity N/A
Completed NCT01336517 - Evaluation of the Effect of an Ankle Foot Orthoses for Ambulatory Function N/A
Recruiting NCT05767437 - The Effects of Reaching Task Following Selective Trunk Stability Exercise N/A
Recruiting NCT05683158 - Compensatory Kinematic Movements in Various Directions After Stroke
Completed NCT04826900 - Wearable Robotic System and Robotic Mirror Therapy in Spastic Hemiplegia Post Botulinum Toxin Injection N/A